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Summary Although vasospastic angina (VSA) is usually controlled by medications,
refractory or lethal cases are occasionally encountered. We performed bilateral
endoscopic thoracic sympathectomy (ETS) in 5 male patients with refractory VSA.
Prior to ETS, stellate ganglion blockade was performed in 4 patients to reduce
VSA attacks and to conﬁrm the effect of sympathetic blockade. Under endoscopic
guidance, the second to fourth thoracic sympathetic ganglia were ablated with a
YAG-laser. No patient had complications after ETS, including major sweating abnor-
malities. In 4 of 5 patients, ETS relieved all VSA symptoms. ST-segment elevation
often detected before ETS was absent on repeated ambulatory 24-h Holter monitor-
ing after ETS. ETS is an effective strategy for the treatment of refractory VSA.
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asospastic angina (VSA) is caused by the spasm of a
oronary artery even without organic stenosis. The
ncidence of VSA is higher in Japan than in Western
ountries. Although VSA is usually controllable by
edications such as calcium channel blockers, we
ccasionally encounter cases refractory to medical
reatment that often become lethal. The mecha-
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ism of coronary spasm has not been fully clariﬁed;
lternation of autonomic nervous tone is thought
o be a major factor [1,2]. Although various tri-
ls to alter autonomic tone have been performed,
here is no established treatment for refractory VSA
ases. Since experimental studies have shown that
timulation of the sympathetic ganglion induces
onstriction of coronary arteries, stellate ganglion
lockade (SGB) has been tried for refractory organic
ngina in some reports. However, the effects of
GB were transient in most cases. In the present
Ltd on behalf of Japanese College of Cardiology.
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Figure 1 The number of medications for vasospastic
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study, we performed bilateral endoscopic thoracic
sympathectomy (ETS) for high-risk patients with
refractory VSA.
From 2001 to 2006, we experienced 5 male
patients with VSA refractory to intensive medica-
tion therapies. In all patients, VSA was diagnosed
based upon typical symptoms such as morning rest
angina with ST-segment elevation in more than 2
leads of the 12-lead electrocardiogram, 2 leads
with ST-elevation on the ambulatory 24-h Holter
monitor, and/or coronary angiographic ﬁndings with
a positive response to intracoronary acetylcholine
(ACh) injection. None of the 5 patients had a signif-
icant organic stenotic lesion in any coronary artery.
The patients were treated with calcium channel
blockers, nitrates and/or nicorandil, and also with
other coronary vasodilators including salpogrelate,
quinapril, bunazosin, and/or denopamine, possi-
bly effective for coronary vasospasm (Table 1).
Nevertheless, their VSA symptoms could not be
controlled. For these patients, we performed EST
under the approval of our ethical committee. Writ-
ten informed consent was given by each patient.
Prior to ETS, we ﬁrst tried SGB by a standard
method using the paratracheal technique with a 25-
gauge needle inserted at the Chassaignac tubercle
on the sixth cervical vertebra in 4 of the 5 patients.
The concentration and volume of local anesthetics
were carefully adjusted on an individual basis by
each physician. Development of Horner’s syndrome
(ptosis and myosis) was conﬁrmed as objective
evidence of a successful block. The SGB was repeat-
edly performed for several days. Although SGB was
effective in relieving angina symptoms, the effect
was transient and we then performed ETS. In one
patient (case 4 in Table 1), ETS was performed with-
out prior SGB.
ETS was performed in all 5 patients based upon
a previously described technique [3,4]. Brieﬂy,
patients were intubated with an endotracheal tube
under general anesthesia and placed in a semi-
reclining position with both arms in abduction.
The pleural cavity was accessed via a Surginee-
dle in the axillary fossa, and approximately 2 l of
carbon dioxide was insufﬂated into the pleural cav-
ity. A modiﬁed urological electroresectoscope was
introduced via the same incision in the axillary
fossa to visualize the upper thoracic cavity. The
sympathetic chain was identiﬁed in the immedi-
ate vicinity of the costovertebral joint. The second
to fourth thoracic sympathetic ganglia, including
the rami communicantes, were ablated by a YAG-
laser. After exsufﬂation of gas, the procedure was
repeated on the contralateral side. The operation
time was less than 30min in all 5 patients. No major
complications occurred, except for the artiﬁcial
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wngina (VSA) before ETS, on discharge, and 12 months
fter ETS. The ETS successfully reduced the medications
sed in 4 of 5 patients.
neumothorax caused by the thoracic endoscopic
echnique. No patients experienced sweating disor-
ers such as dry hands with compensatory sweating,
hich is often a complication of the ETS procedure.
lthough transient exacerbation of VSA attacks
ccurred within a few days after ETS, 4 patients
ere completely free from VSA symptoms there-
fter. In these patients, repeated ambulatory 24-h
olter monitoring did not detect ST-segment ele-
ation and the number of medications for VSA was
educed. The remaining patient (case 4 in Table 1)
ometimes complained of VSA symptoms after ETS,
ut no ST-T changes were documented at that
ime. This patient continued treatment with multi-
le medications. Overall, ETS reduced the average
umber of medications from 6.6 before ETS to 2.2
t 12 months after ETS (Fig. 1).
Many reports suggested that the alternation of
he autonomic nervous regulation participated in
oronary artery spasm [1,2]. Although the precise
ole of the parasympathetic and sympathetic nerves
n coronary spasm has not been clariﬁed, it is well
nown that VSA attacks are often induced by sympa-
hetic activation [2]. Since the heart and coronary
rteries are regulated by the lower cervical and
pper thoracic sympathetic ganglia [5], SGB is
ometimes performed to treat patients with refrac-
ory angina due to organic coronary stenosis [6].
herefore, we ﬁrst applied SGB in our refractory
SA patients and succeeded in relieving their VSA
ymptoms. Although repeated SGB for several days
ould prevent coronary artery spasm, the effect
as transient in our VSA patients. We hypothesized
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Table 1 Patients’ characteristics
Case Age Gender ST elevation at attack CAG ACh test Complication Medications
1 41 M II, III, aVF on 12 lead-ECG No stenosis LAD 100%, LCX 90% Vf, AV block Diltiazem, amlodipine,
nicorandil, ISMN, TNG,
sarpogrelate, denopamine
2 69 M I, aVL, V1-6 on 12 lead-ECG No stenosis No operation Diltiazem, amlodipine,
nicorandil, ISMN, TNG,
sarpogrelate,
denopamine, bunazocine,
quinapril
3 71 M II, III, aVF on 12 lead-ECG No stenosis No operation AMI Diltiazem, amlodipine,
nicorandil, ISMN, TNG,
sarpogrelate, simvastatin
4 65 M II, III, aVF on 12 lead-ECG No stenosis RCA 100% Vf Diltiazem, amlodipine,
nicorandil, ISMN, TNG,
trandolapril
5 40 M CM5, NASA on ambulatory 24 h ECG No stenosis No operation CPR Diltiazem, amlodipine,
nicorandil, ISDN, ISMN,
TNG, sarpogrelate,
bunazocine
M, male; LAD, left anterior descending artery; LCX, left circumﬂex artery; Vf, ventricular ﬁbrilation; AV block, atrioventricular block; AMI, acute myocardial infarction; CPR,
cardiopulmonary resuscitation; ISMN, isosorbide mononitrate; TNG, nitroglycerine; ISDN, isosorbide dinitrate.
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that methods producing more sustained sympa-
thetic blockade might produce long-term relief of
symptoms if the patients responded to SGB. A
previous report showed that ETS had a long-term
effect on cardiac autonomic tone [7]. ETS is a
therapeutic tool for palmer hyperhidrosis, reﬂex
sympathetic dystrophy, circulatory disturbances of
the upper extremities, and refractory angina in
the presence of organic coronary stenosis [3,4,8,9].
To our knowledge, this is the ﬁrst report describ-
ing the application of ETS for refractory VSA. In
our experience, ETS showed long-term efﬁcacy for
VSA. However, there was concern that ETS reduced
only VSA symptom, but did not suppress coro-
nary artery spasm. Silent coronary spasm might
increase the risk of sudden major events. There-
fore, we carefully performed electrocardiographic
monitoring and repeated ambulatory 24-h Holter
monitoring, but there were no evidences of silent
ischemic ST-T changes in any of the patients. Thus,
ETS might reduce not only symptoms but also the
frequency and degree of coronary vasospasm.
Recently, several case reports indicates stent
implantation for diffuse and multiple coronary
spasm with VSA refractory to optimal therapy,
[10] but stenting for spastic coronary artery with-
out organic stenotic lesion is still controversial. It
has been reported that an oral 1-adrenoreceptor
selective antagonist denopamine, which was also
administered in one of our cases (case 1 in Table 1),
is effective in VSA refractory to conventional medi-
cal therapies [11]. Sympathetic denervation by ETS
for VSA seems to be contradictory to denopamine
therapy that accelerates sympathetic nerve activ-
ity. However, denopamine for VSA is relatively low
dose, and the mechanism of the effect is coro-
nary vasodilatory action by a weak stimulation of
1-adrenoreceptor that is predominantly found in
the conduit coronary artery possibly without sym-
pathetic nerve activation [12].
To establish the ETS as an effective therapeu-
tic strategy for refractory VSA, we should try more
effort. Since the ETS causes a shift of sympa-
thovagal balance toward parasympathetic tone,
simultaneous assessment of autonomic response by
[
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eart rate variability would be rational, although
e have no such data in these 5 cases. However, we
elieve that our 5 cases provide evidence that the
TS is a sound therapeutic option for VSA refractory
o any medical treatments.
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